Skip to content
Study details
Enrolling now

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

Eli Lilly and Company
NCT IDNCT07285018ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

150

Study length

about 1.6 years

Ages

18+

Locations

36 sites in AL, AZ, CA +15

About this study

This trial is testing a treatment called LY4065967 for people with diabetic peripheral neuropathic pain. The goal is to see if this treatment is safe and effective.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take LY4065967
  • 2.Take Placebo
PhasePhase 2
Primary goalChange from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)

Secondary: Change From Baseline in the Brief Pain Inventory-Short Form Modified (BPI-SFM) Total Pain Interference Score, Change from Baseline in Emotional Functioning as Measured by the EuroQol-5D 5 Level Questionnaire (EQ 5D 5L), Change from Baseline in Overall Improvement as Measured by Patient's Global Impression of Change (PGI-C), Change from Baseline in Sleep Scale from the Medical Outcomes Study (MOS Sleep Scale), Change from Baseline in Worst Pain Intensity as Measured by NRS